At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Gamma-Secretase Inhibitor RO4929097 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Gamma-Secretase Inhibitor RO4929097 and Laboratory Biomarker Analysis for Recurrent Fallopian Tube Carcinoma and 5 related conditions. Completed, enrolled 45 participants across 12 sites in 2 countries.
Detailed Summary
This phase II trial is studying the side effects and how well RO4929097 works in treating patients with recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionOct 2012
Study CompletionAug 2015
TodayJul 2026
First PostedAug 4, 2010
Enrollment StartJul 1, 2010
Primary CompletionOct 1, 2012
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.9 years ago
Interventions
Gamma-Secretase Inhibitor RO4929097drug
Given PO
Laboratory Biomarker Analysisother
Correlative studies